# AstraZeneca Plc  Pooled analyses of the roxadustat global Phase III

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-pooled-analyses-of-the-roxadustat-global-phase-iii/412774541
- Published: 2019-05-10T07:21:29+01:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
today announced top-line results from the pooled cardiovascular (CV) safety analyses
of the global Phase III programme for roxadustat, a first-in-class hypoxia-inducible-
factor prolyl hydroxylase inhibitor (HIF-PHI). The global pivotal Phase III trials
evaluated roxadustat for treatment of anaemia in patients with chronic kidney disease(
CKD) across the non-dialysis-dependent (NDD), incident (newly-initiated) dialysis(
ID), and stable dialysis patient groups.

These pooled CV safety assessments of roxadustat are part of the overall benefit/
risk assessment that will inform discussions with regulatory authorities. One of
the key CV safety endpoints is major adverse CV events (defined as MACE), evaluating
a composite of all-cause mortality, stroke and myocardial infarction in pooled analyses
comparing roxadustat vs. placebo in NDD and vs. epoetin alfa in dialysis-dependent(
DD) patients. Another key CV safety endpoint evaluated MACE plus heart failure requiring
hospitalisation and unstable angina requiring hospitalisation (defined as MACE+).

**Pooled MACE/MACE+ in NDD patients**

In the pooled analysis of over 4,300 patients, and based on the totality of the 
adjudicated evidence, the MACE/MACE+ analyses between roxadustat and placebo showed
no clinically-meaningful difference.

**Pooled MACE/MACE+ in ID patients**

In the pool of 1,500 ID patients, a pre-specified sub-population of DD patients,
MACE/MACE+ results indicate that ID patients on roxadustat do better than those 
who are on epoetin alfa. ID patients are a better population to compare roxadustat
vs. epoetin alfa than the stable dialysis population, where patients are stable 
not only on dialysis but also on erythropoietin.

**Pooled MACE/MACE+ in DD patients**

In the pooled analysis of around 4,000 patients, and based on the totality of the
adjudicated evidence, the MACE/MACE+ analyses between roxadustat and epoetin alfa
showed no clinically-meaningful difference.

Mene Pangalos, Executive Vice President, R&D BioPharmaceuticals, said: “We are pleased
to report these data from the largest clinical programme in the world evaluating
this new class of medicines. These results add to the growing body of positive evidence
to support roxadustat for the treatment of anaemia in chronic kidney disease patients,
following our announcement that the primary efficacy endpoints were met for the 
OLYMPUS and ROCKIES trials in December 2018. There is a significant unmet medical
need among patients living with chronic kidney disease, and we look forward to working
with FibroGen to prepare for regulatory submissions of roxadustat.”

**Further analyses of overall safety are ongoing and will inform the benefit/risk
profile.**

AstraZeneca and FibroGen Inc. (FibroGen) will begin discussions with the US Food
and Drug Administration (FDA) to prepare for regulatory submission, which is anticipated
in the second half of 2019. Roxadustat is currently approved in China for the treatment
of patients with anaemia in DD CKD.

Share on:
